Please use this identifier to cite or link to this item:
Title: What is the optimal GnRH antagonist protocol for ovarian stimulation during ART treatment? A systematic review and network meta-analysis.
Austin Authors: Venetis, C A;Storr, A;Chua, S J;Mol, B W;Longobardi, S;Yin, X;D'Hooghe, T
Affiliation: University of New South Wales, Faculty of Medicine & Health, Centre for Big Data Research in Health & Discipline of Obstetrics and Gynaecology, Sydney, Australia.
Flinders Fertility, Adelaide, SA, Australia.
Austin Health
Department of Obstetrics and Gynaecology, Monash University, Clayton, Australia.
Global Clinical Development, Merck Serono S.p.A, Rome, Italy, an affiliate of Merck KGaA.
EMD Serono Inc., R&D Global Biostatistics, Epidemiology & Medical Writing, Billerica, MA, USA, an affiliate of Merck KGaA.
Merck Healthcare KGaA, Darmstadt, Germany.
Issue Date: 3-Jan-2023 2023
Publication information: Human Reproduction Update 2023
Abstract: Several GnRH antagonist protocols are currently used during COS in the context of ART treatments; however, questions remain regarding whether these protocols are comparable in terms of efficacy and safety.
DOI: 10.1093/humupd/dmac040
ORCID: 0000-0001-9591-7222
Journal: Human Reproduction Update
PubMed URL: 36594696
ISSN: 1460-2369
Type: Journal Article
Subjects: ART
GnRH antagonist
assisted reproductive technologies
controlled ovarian stimulation
live birth
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jun 7, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.